Solid Biosciences Inc.

SLDB Healthcare Biotechnology

Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.

5.53 0.21 −3.66%
Market cap
$615.5M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
n/a
Altman Z
−2.87
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
6.50 5.65 12.59 13.24
Current Ratio
6.74 6.14 13.10 13.82
Net Debt/EBITDA
4.92 3.81 6.63 6.48
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.73 1.08 0.83 0.96
Capex/Depreciation
(1.73) 1.71 0.74 0.15
Interest Coverage
143.03 (9,880.60) — —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.35) (0.61) (0.43) (0.37)
Capex per Share
0.00 (0.01) 0.00 0.00
Free Cash Flow per Share
(0.36) (0.62) (0.43) (0.37)
Cash per Share
2.50 2.16 3.47 2.63
Shareholders Equity per Share
2.31 2.06 3.41 2.60
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.31 2.06 3.41 2.60
Free Cash Flow
(33.56) (54.03) (47.39) (52.74)
Working Capital
208.51 171.98 366.51 366.52
Capital Expenditures
(0.08) (0.48) (0.16) (0.15)
Net Current Asset Value
188.89 152.93 348.03 348.60
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Other line items
Average Payables
5.94 3.73 6.00 4.53
Average Assets
242.87 210.60 383.40 364.44
Average Common Equity
192.49 158.63 334.30 316.18

Fold the line items

Columns are period end dates